Navegar

Colección

Datos Estadísticas

Lista de

Molecular Targeted Therapy
11
"Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk" (2018) Orozco, C.A.;Martinez-Bosch, N.;Guerrero, P.E. (...)Navarro, P. Proceedings of the National Academy of Sciences of the United States of America. 115(16):E3769-E3778
"Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys" (2018) Abiuso, A.M.B.;Varela, M.L.;Haro Durand, L. (...)Mondillo, C. European Journal of Cancer. 91:125-135
"Galectin-1: A jack-of-all-trades in the resolution of acute and chronic inflammation" (2017) Sundblad, V.; Morosi, L.G.; Geffner, J.R.; Rabinovich, G.A. Journal of Immunology. 199(11):3721-3730
"Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase" (2016) Rodriguez, J.B.; Falcone, B.N.; Szajnman, S.H. Expert Opinion on Drug Discovery. 11(3):307-320
"A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis" (2016) Defelipe, L.A.;Do Porto, D.F.;Pereira Ramos, P.I. (...)Marti, M.A. Tuberculosis. 97:181-192
"A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease" (2013) Laderach, D.J.;Gentilini, L.D.;Giribaldi, L. (...)Rabinovich, G.A. Cancer Research. 73(1):86-96
"New antibacterials for the treatment of toxoplasmosis; A patent review" (2012) Rodriguez, J.B.; Szajnman, S.H. Expert Opinion on Therapeutic Patents. 22(3):311-333
"FKBP51 and FKBP52 in signaling and disease" (2011) Storer, C.L.;Dickey, C.A.;Galigniana, M.D. (...)Cox, M.B. Trends in Endocrinology and Metabolism. 22(12):481-490